Dihydromyricetin protects against lipopolysaccharide‑induced cardiomyocyte injury through the toll‑like receptor‑4/nuclear factor‑κB pathway.
Zhou, Meng-Qiao
Dihydromyricetin protects against lipopolysaccharide‑induced cardiomyocyte injury through the toll‑like receptor‑4/nuclear factor‑κB pathway. [electronic resource] - Molecular medicine reports Dec 2017 - 8983-8988 p. digital
Publication Type: Journal Article
1791-3004
10.3892/mmr.2017.7742 doi
Animals
Cardiotonic Agents--pharmacology
Cell Line
Cell Survival--drug effects
Flavonols--pharmacology
Gene Expression Regulation--drug effects
Inflammation--genetics
Inflammation Mediators--metabolism
Lipopolysaccharides
Myocytes, Cardiac--drug effects
NF-kappa B--metabolism
RNA, Messenger--genetics
Rats
Signal Transduction--drug effects
Toll-Like Receptor 4--metabolism
Dihydromyricetin protects against lipopolysaccharide‑induced cardiomyocyte injury through the toll‑like receptor‑4/nuclear factor‑κB pathway. [electronic resource] - Molecular medicine reports Dec 2017 - 8983-8988 p. digital
Publication Type: Journal Article
1791-3004
10.3892/mmr.2017.7742 doi
Animals
Cardiotonic Agents--pharmacology
Cell Line
Cell Survival--drug effects
Flavonols--pharmacology
Gene Expression Regulation--drug effects
Inflammation--genetics
Inflammation Mediators--metabolism
Lipopolysaccharides
Myocytes, Cardiac--drug effects
NF-kappa B--metabolism
RNA, Messenger--genetics
Rats
Signal Transduction--drug effects
Toll-Like Receptor 4--metabolism